Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.cipla.com | |
Market Cap | 72,696.02 Cr. | |
Enterprise Value(EV) | 71,714.15 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 32.69 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 27.55 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.41 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 286.32 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 3.15 | Calculated using Price: 900.65 |
Dividend Yield | 0.56 | Period Ending 2022-03 |
No. of Shares Subscribed | 80.72 Cr. | 807,150,593 Shares |
FaceValue | 2 | |
Company Profile | ||
The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets. |
1 Day |
|
+1.44% |
1 Week |
|
+2.70% |
1 Month |
|
-0.60% |
3 Month |
|
-16.22% |
6 Month |
|
-19.24% |
1 Year |
|
-11.57% |
2 Year |
|
+10.48% |
5 Year |
|
+65.79% |
10 Year |
|
+137.17% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 14.89 | 12.10 | 12.61 | 8.72 | 10.65 | 10.37 | 10.09 | 14.13 | 13.10 | |
Return on Capital Employed (%) | 19.05 | 15.33 | 13.24 | 8.28 | 10.20 | 11.94 | 12.53 | 17.85 | 17.24 | |
Return on Assets (%) | 10.49 | 7.85 | 7.28 | 4.97 | 6.52 | 6.50 | 6.56 | 9.95 | 9.94 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 10,050 | 10,801 | 11,516 | 12,544 | 14,229 | 15,012 | 15,763 | 18,327 | 20,842 | 21,884 | |
Non Curr. Liab. | 2,028 | 2,418 | 1,407 | 4,513 | 4,259 | 4,646 | 2,972 | 1,660 | 622 | 117 | |
Curr. Liab. | 2,564 | 3,881 | 7,776 | 3,374 | 3,832 | 3,772 | 4,393 | 4,591 | 4,913 | 5,309 | |
Minority Int. | 50 | 180 | 350 | 438 | 352 | 332 | 294 | 259 | 276 | 285 | |
Equity & Liab. | 14,692 | 17,281 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,837 | 26,652 | 27,596 | |
Non Curr. Assets | 9,040 | 9,689 | 12,208 | 12,064 | 11,859 | 11,335 | 11,717 | 11,628 | 11,925 | 11,690 | |
Curr. Assets | 5,652 | 7,591 | 8,841 | 8,736 | 10,814 | 12,425 | 11,704 | 13,181 | 14,711 | 15,906 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 14,692 | 17,281 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,837 | 26,652 | 27,596 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 10,173 | 11,345 | 13,595 | 14,394 | 15,156 | 16,362 | 17,132 | 19,160 | 21,763 | 22,274 | |
Other Income | 265 | 166 | 208 | 229 | 358 | 477 | 369 | 270 | 322 | 405 | |
Total Income | 10,439 | 11,511 | 13,803 | 14,623 | 15,513 | 16,839 | 17,501 | 19,429 | 22,085 | 22,679 | |
Total Expenditure | -8,040 | -9,184 | -11,115 | -11,919 | -12,329 | -13,265 | -13,951 | -14,911 | -17,251 | -17,671 | |
PBIDT | 2,398 | 2,327 | 2,688 | 2,704 | 3,184 | 3,574 | 3,550 | 4,518 | 4,834 | 5,008 | |
Interest | -146 | -168 | -207 | -159 | -114 | -168 | -197 | -161 | -106 | -93 | |
Depreciation | -373 | -505 | -754 | -1,323 | -1,323 | -1,326 | -1,175 | -1,068 | -1,052 | -1,116 | |
Taxation | -463 | -400 | -332 | -180 | -250 | -570 | -631 | -889 | -934 | -1,052 | |
Exceptional Items | -78 | -182 | -58 | ||||||||
PAT | 1,417 | 1,254 | 1,395 | 1,042 | 1,419 | 1,510 | 1,547 | 2,401 | 2,559 | 2,689 | |
Minority Interest | -16 | -48 | -23 | -29 | -6 | 35 | 47 | 16 | -30 | -44 | |
Share Associate | -12 | -25 | -12 | -7 | -3 | -17 | -47 | -13 | -13 | -7 | |
Other Related Items | |||||||||||
Consolidated Net Profit | 1,388 | 1,181 | 1,360 | 1,006 | 1,411 | 1,528 | 1,547 | 2,405 | 2,517 | 2,638 | |
Adjusted EPS | 17 | 15 | 17 | 13 | 18 | 19 | 19 | 30 | 31 | 33 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 1,398 | 1,563 | 1,173 | 1,741 | 2,382 | 1,463 | 1,691 | 3,068 | 3,755 | 3,326 | |
Cash Fr. Inv. | -2,063 | -1,250 | -941 | -4,523 | -1,310 | -854 | -1,669 | 104 | -2,387 | -1,872 | |
Cash Fr. Finan. | 718 | -266 | 165 | 3,104 | -1,326 | -385 | -349 | -2,949 | -1,240 | -1,600 | |
Net Change | 53 | 48 | 397 | 322 | -254 | 223 | -326 | 224 | 129 | -146 | |
Cash & Cash Eqvt | 143 | 176 | 564 | 858 | 610 | 853 | 508 | 742 | 790 | 658 |
Wed, 29 Mar 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we herein mention the schedule of Analyst / Institutional Investor Meetings with the Company. |
Fri, 17 Mar 2023
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby notify that the Operations and Administrative Committee of the Company on 17th March 2023 has allotted 6 663 fully paid-up equity shares of INR 2 each pursuant to exercise of employee stock options under the Employee Stock Option Scheme 2013-A of the Company.Consequently the issued subscribed and paid-up share capital of the Company stands increased to INR 1 61 43 01 186 comprising of 80 71 50 593 equity shares of face value INR 2 each. |
Tue, 14 Mar 2023
Announcement under Regulation 30 (LODR)-Diversification / Disinvestment In compliance with the provisions of Regulation 30 of the SEBI Listing Regulations we hereby notify that the Company and its wholly owned subsidiaries Cipla (EU) Limited UK and Meditab Holdings Limited Mauritius have entered into a Share Purchase Agreement with Africa Capitalworks SSA 3 on 14th March 2023 for sale of 51.18% stake held in Cipla Quality Chemical Industries Limited (CQCIL) Uganda. Subsequent to the sale CQCIL will cease to be a subsidiary of the Company. Details required to be disclosed under the SEBI Listing Regulations 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015 have been provided in Annexure - I to this letter. |
Fri, 31 Mar 2023 |
|
|
|
|
|